Assess the Plasma, Epithelial Lining, and Alveolar Macrophage Concentrations of Intravenous Meropenem-Pralubactam (Meropenem/FL058) in China Healthy Adult Participants

Inclusion criteria

• Male or female, aged 18-45 years
• Body mass index (BMI): 19-28 kg/m² , with body weight ≥50 kg.
• Pulmonary function at screening:

• Forced expiratory volume in 1 second (FEV₁) measured/predicted >80%
• Forced vital capacity (FVC) measured/predicted >80%
• All other ventilation and diffusion parameters normal or with no clinical significance.
• Participant capability:

• Ability to communicate effectively with investigators
• Willingness to comply with study procedures
• Voluntary participation with acceptance of bronchoalveolar lavage (BAL)
• Provision of written informed consent.
• Reproductive planning:

• No pregnancy, sperm/egg donation plans from signing informed consent through 28 days after last dose
• Participant and partner must use protocol-approved contraception.

Exclusion criteria

• Hypersensitivity to cephalosporins or carbapenem antibiotics.
• History or current diagnosis of respiratory system diseases.
• History or current diagnosis of coagulation disorders.
• Clinically significant diseases in cardiovascular, endocrine, neurological, digestive, hematological, metabolic, or psychiatric systems judged by the investigator to interfere with study outcomes.
• History of smoking or positive nicotine test during screening.
• Prior surgery involving pharynx, trachea/bronchi, or lungs.
• Drug abuse history within 1 year prior to screening or positive urine drug screen at screening.
• Alcohol intake >14 units/week on average within 6 months prior to screening.
• Participation in other clinical trials with investigational drugs/devices within 3 months prior to screening.
• Blood donation/loss ≥400 mL or blood product transfusion within 3 months prior to screening.
• Respiratory infections (bacterial/fungal/viral) within 2 weeks prior to screening (e.g., upper/lower respiratory tract infections).
• Use of any medication/vaccination within 14 days prior to screening or planned vaccination during the study.
• Clinically significant abnormalities in physical examination, 12-lead ECG, or imaging at screening per investigator's judgment.
• Pregnancy, lactation, or positive serum pregnancy test at screening.